Market: NMS |
Currency: USD
Address: 107 Spring Street
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
📈 Atossa Therapeutics, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$18.33
-
Upside/Downside from Analyst Target:
2,755.21%
-
Broker Call:
6
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
<0%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
-
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Atossa Therapeutics, Inc.
| Date | Reported EPS |
|---|
| 2026-03-25 | -1.34 |
| 2025-11-12 | -1.05 |
| 2025-08-12 | -1.05 |
| 2025-05-13 | -0.75 |
| 2025-03-25 | -0.75 |
| 2024-11-12 | -0.9 |
| 2024-08-12 | -0.75 |
| 2024-05-13 | -0.75 |
| 2024-04-01 | -0.9 |
| 2023-11-13 | -0.75 |
| 2023-08-14 | -1.2 |
| 2023-05-15 | -0.75 |
| 2023-03-22 | -0.9 |
| 2022-11-07 | -0.9 |
| 2022-08-08 | -0.75 |
| 2022-05-09 | -0.6 |
| 2022-02-28 | -0.6 |
| 2021-11-15 | -0.6 |
| 2021-08-13 | -0.9 |
| 2021-05-14 | -0.6 |
| 2021-03-31 | -13.2 |
| 2020-11-13 | -5.1 |
| 2020-08-13 | -6.45 |
| 2020-05-13 | -4.8 |
| 2020-03-26 | -3.9 |
📰 Related News & Research
🔍 View more Reports
